The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

It contains tirzepatide, which is the active ingredient in the brand-name drug Mounjaro. If you cannot take Mounjaro for medical reasons, you may need compounded tirzepatide.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the need for equitable treatment strategies.

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

(HealthDay News) — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes, according ...